New experimental drug cagrilintide (AM833), when combined with emaglutide, shows potential for treatment of obesity

An early study of a new experimental drug to treat obesity known as cagrilintide shows that, when combined with semaglutide 2.4 mg, the combination leads to more weight loss than semaglutide 2.4 mg alone and is well tolerated. This phase 1 study, which was recently published in The Lancet will be presented at this year's European Congress on Obesity (held online, 10-13 May) by Dr. Lone Enebo, Novo Nordisk A/S, Denmark, on behalf of her colleagues. Novo Nordisk A/S is the manufacturer of both drugs in this study.